ERBB2 and breast carcinoma: For example, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), inhibits the HER2 signaling pathway, thereby suppressing the proliferation and metastasis of HER2-positive breast cancer cells [148].